 NEW HAVEN, Conn., Dec. 01, 2022 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. Nasdaq: BTAI, a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a virtual fireside chat at the Bank of America 2022 Biotech SMID Cap Conference on Wednesday, December 7, 2022 at 1:45 p.m. Eastern Time. Management will discuss the Companys neuroscience and immuno-oncology programs as well as its artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process. They will also discuss the Companys ongoing commercial launch strategy for IGALMITM dexmedetomidine sublingual film. 